Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin
07:45 EDT 9 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Bristol-Myers
Squibb Company (NYSE:BMY) and AstraZeneca
(LSE:AZN) announced that following the successful completion of the
acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb,
AstraZeneca has made an initial pa...
Other Sources for this Article
Bristol-Myers Squibb:
Media Enquiries
Jennifer
Fron Mauer, 609-252-6579, jennifer.mauer@bms.com
Laura
Hortas, 609-252-4587, laura.hortas@bms.com
Investors
Timothy
Power, 609-252-7509, timothy.power@bms.com
or
AstraZeneca:
Media
Enquiries
Sarah Lindgreen, +44 20 7604 8033
Investor
Enquiries UK
James Ward-Lilley, +44 20 7604 8122 / mob: +44
7785 432613
Karl Hård, +44 20 7604 8123 / mob: +44 7789 654364
More From BioPortfolio on "Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
